is to research the efficiency of fluvoxamine action on disturbing and depressive disorder at patients with the hypertensive illness, complicated by chronic heart failure.Design and Method:
34 patients with the hypertensive illness complicated by chronic heart failure had been surveyed. Patients were divided into 2 groups: the first, main group, included 17 patients receiving complex treatment of somatic disease and disturbing and depressive disorders by 50 mg fluvoxamine 1 time per day, in the evening for 28 days; the second, control group, included 17 patients receiving only basic therapy of somatic disease. For verification of the diagnosis were used the general clinical-laboratory researches. The hospital anxiety and depression scale (HADS) was applied to the assessment of disturbing and depressive disorder.Results:
The results showed that the level of disturbing and depressive disorder at patients after the course of fluvoxamine treatment appeared much lower than initial condition, and also psychopharmacological value considerably raises for its combination with hypotensive therapy and low degree of side effects. Level of disturbing and depressive disorder according to HADS, in group 1 made up initial total point 16,8 ± 1,5; in group 2 it made up 17,8 ± 1,9 (ρ ≤ 0,01). After 4 weeks of treatment this indicator also considerably decreased in group 1 to 11,4 ± 1,3* points; and in group 2 to 13,4 ± 1,5. Patients after fluvoxamine therapy noted subjective improvement of health that was reflected in their behavior. At the patients, not receiving in fluvoxamine complex therapy, indicators of dynamics on scales of HADS, reduced only as a result of decrease in intensity of somatic symptoms.Conclusions:
Thus, the carried-out research showed that fluvoxamine is effective and safe remedy for treatment of neurotic disorders of disturbing depressive range at patients with the hypertensive illness, complicated by chronic heart failure.